A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

  • Cancer
  • Breast Cancer
  • Breast Cancer Er-Positive
  • Breast Cancer HER-2 Negative
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:


This trial runs in
  • Albuquerque
  • Aschaffenburg
  • Ashland
  • Avon
  • Baltimore
  • Boston
  • Brighton
  • Cleveland
  • Dallas
  • Danvers
  • Erlangen
  • Everett
  • Fort Worth
  • Frankfurt am Main
  • Hamburg
  • Honolulu
  • Houston
  • Lincoln
  • London
  • Manchester
  • Marietta
  • Melbourne
  • Miami
  • Minneapolis
  • München
  • Newmarket
  • North Sydney
  • Nottingham
  • Ottawa
  • Palm Springs
  • Phoenix
  • Ravensburg
  • Rostock
  • San Diego
  • Santa Rosa
  • Sherbrooke
  • Sioux Falls
  • South Brisbane
  • Springdale
  • Toronto
Trial Identifier:

NCT03584009 2017-005118-74 WO40181

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a Phase II, multicenter, open-label, randomized study to compare the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone in women with ER+, HER2-negative, locally advanced or Metastatic Breast Cancer (MBC) who experienced disease recurrence or progression during or after treatment with CDK4/6i therapy for at least 8 weeks. As of 9th October 2020, participants in the Venetoclax + Fulvestrant arm, have all discontinued Venetoclax treatment and have continued on Fulvestrant treatment alone.

      Hoffmann-La Roche Sponsor
      Phase 2 Phase
      NCT03584009,WO40181,2017-005118-74 Trial Identifier
      Venetoclax, Fulvestrant Treatments
      Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer Condition
      Official Title

      A Phase II, Multicenter, Randomized Study To Compare The Efficacy Of Venetoclax Plus Fulvestrant Versus Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

      Eligibility Criteria

      Female Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Histological or cytological confirmation of estrogen receptor-positive (ER+) invasive carcinoma of the breast. ER+, HER2- negative invasive carcinoma of the breast with evaluable sample for BCL-2 IHC value at the time of screening. Participants who were originally diagnosed with HER2-positive breast cancer that converted to HER2-negative MBC are not eligible.
      • Evidence of metastatic or locally advanced disease not amenable to surgical or local therapy with curative intent.
      • Be postmenopausal or pre- or perimenopausal women amenable to being treated with the luteinizing hormone-releasing hormone (LHRH) agonist goserelin.
      • Participants must not have received more than two prior lines of hormonal therapy in the locally advanced or metastatic setting. In addition, at least one line of treatment must be a CDK4/6i AND participants must have experienced disease recurrence or progression during or after CDK4/6i therapy, which must have been administered for a minimum of 8 weeks prior to progression.
      • Participants for whom endocrine therapy (e.g., fulvestrant) is recommended and treatment with cytotoxic chemotherapy is not indicated at the time of entry into the study, as per national or local treatment guidelines.
      • Women of childbearing potential (i.e., not postmenopausal for at least 12 months or surgically sterile) must have had a negative serum pregnancy test result at screening, within 14 days prior to the first study drug administration.
      • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use non-hormonal contraceptive methods with a failure rate of <1% per year during the treatment period and for up to 2 years after the last dose of study drug (or based on the local prescribing information for fulvestrant). Women must refrain from donating eggs during this same period.
      • Willing to provide tumor biopsy sample.
      • Had at least one measurable lesion via RECIST v1.1.
      • Had an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1.
      • Had adequate organ and marrow function.
      • Had a life expectancy > 3 months.
      • To full fill the coagulation requirements for patient with or without therapeutic anticoagulation.
      Exclusion Criteria
      • Prior treatment with fulvestrant or other selective estrogen receptor degraders (SERDs), venetoclax, or any agent whose mechanism of action is to inhibit BCL-2.
      • Pregnant, lactating, or intending to become pregnant during the study.
      • Known untreated or active Central Nervous System (CNS) metastases (progressing or requiring anticonvulsants or corticosteroids for symptomatic control.
      • Prior chemotherapy in the locally advanced or metastatic setting regardless of the duration of the treatment.
      • Any anti-cancer therapy received within 21 days of the first dose of study drug, including chemotherapy, radiotherapy, hormonal therapy, immunotherapy, antineoplastic vaccines, or other investigational therapy. (Radiotherapy with palliative intent to non-target sites is allowed).
      • Concurrent radiotherapy to any site or prior radiotherapy within 21 days of Cycle 1 Day 1 or previous radiotherapy to the target lesion sites (the sites that are to be followed for determination of a response) or prior radiotherapy to > 25% of bone marrow.
      • Current severe, uncontrolled, systemic disease (e.g., clinically significant cardiovascular, pulmonary, metabolic or infectious disease.
      • Any major surgery within 28 days of the first dose of study drug or anticipation of the need for major surgery during the course of study treatment.
      • Consumption of one or more of the following within 3 days prior to the first dose of study drug: Grapefruit or grapefruit products; Seville oranges including marmalade containing Seville oranges; Star fruit (carambola).
      • Administration within 7 days prior first dose of study treatment of Steroid therapy for anti-neoplastic intent, Strong or moderate CYP3A inhibitors or Strong or moderate CYP3A inducers.
      • Need for current chronic corticosteroid therapy (> 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids).
      • Known infection with (human immunodeficiency virus) HIV or human T-cell leukemia virus 1.
      • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day).
      • Positive test results for hepatitis B core antibody (HBcAb) or hepatitis C virus (HCV) antibody at screening. Participants who were positive for HCV antibody should have been negative for HCV by PCR to be eligible for study participation. Participants with a past or resolved hepatitis B virus (HBV) infection (defined as having a positive total HBcAb and negative hepatitis B surface antigen [HbsAg]) may be included if HBV DNA is undetectable. These participants should have been willing to undergo monthly DNA testing.
      • Participants who had a positive HCV antibody test are eligible for the study if a PCR assay is negative for HCV RNA.
      • History of other malignancies within the past 5 years except for treated skin basal cell carcinoma, squamous cell carcinoma, non-malignant melanoma <= 1.0 mm without ulceration, localized thyroid cancer, or cervical carcinoma in-situ.
      • Administration of a live, attenuated vaccine within 4 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study.
      • Cardiopulmonary dysfunction.
      • Other medical or psychiatric conditions that, in the opinion of the investigatory, may interfere with the participant's participation in the study.
      • Inability or unwillingness to swallow pills or receive intramuscular (IM) injections.
      • History of malabsorption syndrome or other condition that would interfere with enteral absorption.
      • History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis) or active bowel inflammation (e.g., diverticulitis).
      • Concurrent hormone replacement therapy.
      • Inability to comply with study and follow-up procedures.
      • History or active cardiopulmonary dysfunction.
      • Known hypersensitivity to any of the study medications (fulvestrant, venetoclax) or to any of the excipients.

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now